Clinical pharmacology of bispecific antibody constructs

Chetan Rathi, Bernd Meibohm

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The confluence of rapid scientific advancements especially in protein engineering and recombinant technology, unmet medical needs, and commercial incentives have led to the development of the next generation of therapeutic proteins. Bispecific antibody constructs are one of the novel strategies that is being pursued, combining the ability to bind simultaneously to two distinct targets and the advantages of purpose-designed and optimized antibody-based scaffolds. Their pharmacokinetic and pharmacodynamic properties, including their immunogenic potential, are closely related to their structural features and ability to interact with disposition mechanisms of immunoglobulin molecules. Catumaxomab and blinatumomab are bispecific constructs that are approved for clinical use and have provided clinical pharmacology data for this novel class of therapeutics. This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage.

Original languageEnglish (US)
Pages (from-to)S21-S28
JournalJournal of clinical pharmacology
Volume55
Issue numberS3
DOIs
StatePublished - Jan 1 2015

Fingerprint

Bispecific Antibodies
Clinical Pharmacology
Aptitude
Protein Engineering
Knowledge Bases
Immunoglobulins
Motivation
Proteins
Therapeutics
Pharmacokinetics
Technology
Antibodies

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Clinical pharmacology of bispecific antibody constructs. / Rathi, Chetan; Meibohm, Bernd.

In: Journal of clinical pharmacology, Vol. 55, No. S3, 01.01.2015, p. S21-S28.

Research output: Contribution to journalArticle

@article{f0459be1b0e049bd8e8e6a9349992555,
title = "Clinical pharmacology of bispecific antibody constructs",
abstract = "The confluence of rapid scientific advancements especially in protein engineering and recombinant technology, unmet medical needs, and commercial incentives have led to the development of the next generation of therapeutic proteins. Bispecific antibody constructs are one of the novel strategies that is being pursued, combining the ability to bind simultaneously to two distinct targets and the advantages of purpose-designed and optimized antibody-based scaffolds. Their pharmacokinetic and pharmacodynamic properties, including their immunogenic potential, are closely related to their structural features and ability to interact with disposition mechanisms of immunoglobulin molecules. Catumaxomab and blinatumomab are bispecific constructs that are approved for clinical use and have provided clinical pharmacology data for this novel class of therapeutics. This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage.",
author = "Chetan Rathi and Bernd Meibohm",
year = "2015",
month = "1",
day = "1",
doi = "10.1002/jcph.445",
language = "English (US)",
volume = "55",
pages = "S21--S28",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "S3",

}

TY - JOUR

T1 - Clinical pharmacology of bispecific antibody constructs

AU - Rathi, Chetan

AU - Meibohm, Bernd

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The confluence of rapid scientific advancements especially in protein engineering and recombinant technology, unmet medical needs, and commercial incentives have led to the development of the next generation of therapeutic proteins. Bispecific antibody constructs are one of the novel strategies that is being pursued, combining the ability to bind simultaneously to two distinct targets and the advantages of purpose-designed and optimized antibody-based scaffolds. Their pharmacokinetic and pharmacodynamic properties, including their immunogenic potential, are closely related to their structural features and ability to interact with disposition mechanisms of immunoglobulin molecules. Catumaxomab and blinatumomab are bispecific constructs that are approved for clinical use and have provided clinical pharmacology data for this novel class of therapeutics. This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage.

AB - The confluence of rapid scientific advancements especially in protein engineering and recombinant technology, unmet medical needs, and commercial incentives have led to the development of the next generation of therapeutic proteins. Bispecific antibody constructs are one of the novel strategies that is being pursued, combining the ability to bind simultaneously to two distinct targets and the advantages of purpose-designed and optimized antibody-based scaffolds. Their pharmacokinetic and pharmacodynamic properties, including their immunogenic potential, are closely related to their structural features and ability to interact with disposition mechanisms of immunoglobulin molecules. Catumaxomab and blinatumomab are bispecific constructs that are approved for clinical use and have provided clinical pharmacology data for this novel class of therapeutics. This knowledgebase on the clinical behavior of bispecific therapeutic proteins is poised to rapidly evolve over the next few years with many development programs having entered the clinical development stage.

UR - http://www.scopus.com/inward/record.url?scp=84923363809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923363809&partnerID=8YFLogxK

U2 - 10.1002/jcph.445

DO - 10.1002/jcph.445

M3 - Article

VL - 55

SP - S21-S28

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - S3

ER -